Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 43, Issue 5, 2004, Pages 600-602

  Zalewska Szewczyk, Beata ^a   Andrzejewski, Witalij ^a   Bodalski, Jerzy ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Antibodies; Children; Hypersensivity; L asparaginase

Indexed keywords

ANTIBODY; ASPARAGINASE; ASPARAGINASE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG HYPERSENSITIVITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PHOTOMETRY; PRIORITY JOURNAL;

ADOLESCENT; ANTIBODY FORMATION; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DRUG HYPERSENSITIVITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE;

EID: 4744370294     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20064     Document Type: Article

References (8)

1. Ottgen J, Sucin S, Lutz P, et al. The importance of L-asparaginase (A'Ase) in the treatment of acute lymphoblastic leukemia (ALL) in children: Results of the EORTC 58881 randomized phase III trial showing greater efficacy of Escherichia coli (E. coli) as compared to Erwinia (Erw) A'Ase. Blood 1996;88(Suppl 1): 669A.
2. Müller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998;28:97-113.
3. Albertsen BK, Schrøder H, Jakobsen P, et al. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol 2002;38:310-316.
4. Rizzardi C, Zucchetti M, Monter V, et al. L-asparaginase depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Ann Oncol 2000;11:189-193.
5. Woo MH, Hak LJ, Storm MC, et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998;12:1527-1533.
6. Boos J, Werber G, Ahlke E, et al. Monitoring of asparaginase activity and asparaginase level in children on different asparaginase preparations. Eur J Cancer 1996;32A:1544-1550.
7. Woo MH, Hak LJ, Storm MC, et al. Hypersensivity or development of antibodies to asparaginase does not impact treatment ouycome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000;18:1525-1532.
8. Asselin BL, Whitin JC, Coppola DJ, et al. Comparative pharmacokinetic studies of three asparaginase preparation. J Clin Oncol 1993;11:1780-1786.